Latest Flexion Therapeutics Inc. Stories
WOBURN, Mass., April 18, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc. announced today the presentation of a poster titled "FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis" at Osteoarthritis Research Society International's (OARSI) 2013 World Congress on Osteoarthritis in Philadelphia. Flexion co-founder and chief medical officer, Neil Bodick, M.D., Ph.D., will discuss the findings during the poster session from...
WOBURN, Mass., Jan. 4, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc., a clinical-stage specialty pharmaceutical company developing innovative therapeutics for musculoskeletal disorders, today announced that the company will present at the 31st Annual J.P. Morgan Healthcare Conference. Michael Clayman, M.D., Flexion's chief executive officer, is scheduled to present a corporate overview at 11:30 a.m. PST on Wednesday, January 9, 2013 in the Elizabethan C/D Ballroom of the Westin St....
WOBURN, Mass., Dec. 17, 2012 /PRNewswire/ -- Flexion Therapeutics, Inc. today reported that FX006, its novel intra-articular, sustained release steroid, maintained therapeutic concentrations in the knee joint significantly longer than the most commonly prescribed immediate release (IR) steroid, triamcinolone acetonide (TCA) in a Phase 2 pharmacokinetic study. At six weeks, FX006, a sustained release formulation of TCA, remained in the joint at clinically active concentrations while...
WOBURN, Mass., Dec. 4, 2012 /PRNewswire/ -- Flexion Therapeutics, Inc. today announced that the company has secured $20 million in a Series B financing round led by new investor, Novo Ventures. Flexion's existing investors, 5AM Ventures, Pfizer Venture Investments, Sofinnova Partners and Versant Ventures also participated in the financing. Proceeds will be used to fund late stage clinical development of the company's portfolio of intra-articular, sustained release therapies for the...
WOBURN, Mass., May 30, 2012 /PRNewswire/ -- Flexion Therapeutics, Inc. today reported that its lead osteoarthritis drug candidate, FX005, demonstrated significant pain relief over placebo at four weeks* in a Phase 2 proof-of-concept trial. Top-line data showed FX005, delivered intra-articularly to the knee, was well-tolerated and resulted in prolonged improvement in joint pain and function throughout the 12-week duration of the study. These are the first-ever clinical results...
